Navigation Links
Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
Date:3/14/2011

" commented Fabio M. Benedetti, MD, Chief Medical Officer of Taiho Pharma U.S.A., Inc.

Teysuno™ will be launched in Europe during the second half of 2011.

About Gastric Cancer

With an estimated 934,000 new cases per year (8.6% of all new cancer cases), gastric cancer is the fourth most common cancer worldwide, following lung, breast, and colorectal cancers. It is the second most common cause of cancer-related death, accounting for an estimated 700,000 to 800,000 deaths annually.  Nearly 70% of new cases occur in developing countries; 42% of new cases occur in China alone.

In Europe, gastric cancer is the seventh most common cancer and the sixth most common cause of cancer death, with an estimated annual mortality rate of 118,200.  In general, gastric cancer incidence rates are about twice as high among men as in women. The disease is difficult to cure unless it is diagnosed in its early stages. Unfortunately, because early gastric cancer causes few symptoms, the disease is not usually diagnosed until it has reached an advanced stage. In Europe, the five-year survival rate for gastric cancer is roughly 20% in men and 25% in women. Similarly, in the United States, the five-year survival rate for gastric cancer is 24%, though survival rates improve to 61% if the disease is detected early. However, less than one-quarter of gastric cancers are diagnosed at an early stage in the United States.  In contrast, the five-year survival rate exceeds 50% in Japan, where early gastric cancer is diagnosed relatively frequently due to mass screening efforts, which have been practiced since the 1960s.

About Teysuno

Teysuno™ was authorized for the treatment of gastric cancer in Japan in 1999. Teysuno™ is also authorized for patients with gastric cancer in South Korea, China, Singapore and Taiwan. To date, Teysuno™ has been used by more than 870,000 patients in Japan and Asia.

Ab
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
2. ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment of Stargardts Disease
3. Mylans Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg
4. Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
5. EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
6. Rensselaer professor Daniel Lewis receives NSF CAREER Award
7. Pacific Shore Holdings, Inc. Receives Symbol Change Approval From FINRA
8. Boston College receives W.M. Keck Foundation funding for nanoscale optical microscope
9. CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices
10. Dr. Stefan Strauf of physics at Stevens receives NSF CAREER Award for quantum research
11. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ANGELES , Aug. 4, 2015   California ... the recent acquisition of LifeLine Cryogenics, an east coast ... New York tristate area. LifeLine ... and all prepaid contracts will be honored. ... cryogenics services, offering storage of sperm, eggs, embryos, and ...
(Date:8/3/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Annual Canaccord|Genuity Growth Conference in Boston, ... CEO, William C. Taylor , President and COO, ...
(Date:8/3/2015)... Delaware , August 3, 2015 ... in the commercialization of its Bio-electrical Signal Therapy device ... noninvasive treatment of hard to heal chronic wounds, today ... agreement with Chemipal, an Israeli distributor specializing in medical ... device. Chemipal is a 70 years old, ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
Breaking Biology Technology:FamilyCord Announces Acquisition of LifeLine Cryogenics 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3
... Advanced Instruments, Inc . today introduced the ... automation-friendly osmometer for the biopharmaceutical industry."The ... designed for -- and completely redefines -- automation ... said Kelly Peterson, Product Manager, Advanced Instruments ( ...
... announced today,promising findings on the in vitro ... cancer developed on the basis of its ... both in vitro and in vivo models,Santaris ... inhibition of disease-associated microRNAs due to their ...
... April 20 Psylin Neurosciences Inc., ... Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. announced today ... novel compound, PSN0041, for the treatment of depression.(Logo: ... )PSN0041, a peptide from Amylin,s proprietary polypeptide hormone ...
Cached Biology Technology:Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 2Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 3LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs 2Psylin Neurosciences Commences Development of Compound for Depression 2Psylin Neurosciences Commences Development of Compound for Depression 3
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/13/2015)... July 13, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced sampling of ClearPad ® ... driver integration (TDDI) product targeting smartphones and tablets. ... combine Synaptics , best-in-class touch controller IP ... technology developed in the company,s Japan Design Center. ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... In a discovery that seems counterintuitive, a study appearing ... has found that tendons in high-stress and strain ... frequently than low-stress tendons. This study sheds some light ... during aging. Tendons, composed of collagen and other ...
... a defect in cellular pathways that provides a new explanation ... known as craniosynostosis. Mutations of the WNT and ... regulate bone formation at the stem cell level, according to ... Science Signaling . "Our work contributes to the overall ...
... Rensselaer Polytechnic Institute and principal investigator Glenn Monastersky have been ... Stem Cell Science Program (NYSTEM) of the Empire State Stem ... the Center for Biotechnology and Interdisciplinary Studies (CBIS), said the ... excellence for basic stem cell research within the CBIS. ...
Cached Biology News:High-strain tendons repair less frequently 2Stem-cell disruption induces skull deformity, UR study shows 2Rensselaer Polytechnic Institute wins $2.45 million grant to support stem cell research 2
...
...
...
... silica based spin filter membrane to isolate DNA ... band is cut from an agarose gel and ... gel slice is melted irreversibly in a high ... to the silica spin filter membrane and washed ...
Biology Products: